MNPR slides nearly 5% as technical indicators confirm continued short-term weakness

Traders Union
All News
Stocks
Monopar Therapeutics slides 4.93% today

Highlights

Shares of Monopar Therapeutics trade below short- and medium-term moving averages but remain above the 200-day, supporting a long-term bullish structure.
Technical indicators show negative momentum and oversold conditions, with sellers dominating short-term and intraday trading.
Expected price range over the next five trading days is $92.245 to $102.715, with 57% probability of further downside.

Anton Kharitonov, expert at Traders Union, sees the persistent decline in Monopar Therapeutics as a sign of deep bearish sentiment. The absence of news catalysts leaves the trend fully dictated by technical factors and continued selling momentum. Kharitonov points to the price trading below key moving averages and oversold readings as signals that recovery is unlikely without an external trigger. He also notes that heavy intraday selling and low MACD reinforce the cautious stance. "Without fresh news or catalysts, I see little reason for bulls to step in at these levels," concludes Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, remains constructive even amid short-term weakness in Monopar Therapeutics. He emphasizes the continued long-term bullish structure above the 200-day moving average and sees oversold momentum readings as an opportunity, not a risk. Karapetjanc adds that the market offers multiple setups as consolidation creates the groundwork for future upside. "Despite near-term volatility, I expect further growth once the stock reclaims resistance above $99.52," he states.

Sholanke Dele, market strategist, believes negative momentum continues to pressure Monopar Therapeutics. Dele stresses that lack of supporting news undermines confidence and leaves the stock vulnerable to further weakness. He cautions that bearish intraday moves reflect weak sentiment and may persist. "Market players should remain defensive while the price hovers near support at $92.245," he warns.

Short-term bearish momentum contrasts with long-term bullish structure

Monopar Therapeutics is trading below both its 20-day and 50-day moving averages at $111.3178 and $111.6609, respectively, but remains above the 200-day at $75.9692, confirming long-term bullish structure even as short- and medium-term pressure favors sellers. The near-term ceiling is at $99.52 and the near-term floor is seen at $92.245, with the Ichimoku Kijun at $111.895 confirming resistance remains far overhead. Momentum is negative, with the MACD signaling “Sell” and the ADX at a neutral 19.57. RSI at 38.54, Stochastic RSI at 8.45, CCI at -180.55, and Bull/Bear Power at -4.69 all indicate oversold conditions, with the Awesome Oscillator in agreement with the downtrend. The stock has dropped $5.06 or 4.93% today after an earlier upside gap of $1.42 (1.38%), now trading near the session low. Intraday volatility is 4.05%. Heavy selling at the open and pressure toward session lows underscore the bearish intraday tone and align with momentum readings.

Earlier, analysts noted that Monopar Therapeutics faced continued bearish momentum and elevated downside risk amid persistent technical weakness. The current analysis reaffirms this negative outlook and highlights the $92.245 support as the critical level for traders to monitor in the near term.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.